Macular Edema and Macular Degeneration Market Outlook 2026–2035: Growth Drivers and Industry Forecast
Uncover key drivers, emerging technologies, and competitive movements shaping the macular edema and macular degeneration market from 2026–2035 with trusted insights from The Business Research Company
What size range is anticipated for the Macular Edema and Macular Degeneration Market from 2026 to 2030?
The macular edema and macular degeneration market size has shown strong expansion in recent years. It is projected to increase from $10.33 billion in 2025 to $11.03 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. The growth witnessed during the historic period can be attributed to the rising prevalence of diabetes and retinal disorders, an aging population with an elevated risk of vision impairment, the clinical effectiveness of anti-vegf injections, increasing awareness of macular diseases, and the expansion of ophthalmology clinics.
The market for macular edema and macular degeneration is projected to experience robust expansion over the coming years, predicted to reach $14.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this growth during the forecast period include the increasing worldwide diabetic population, enhanced screening efforts for retinal conditions, a rising need for minimally invasive eye therapies, broader availability of advanced ophthalmic services, and increased healthcare expenditure on maintaining vision. Key trends anticipated in the forecast period encompass a greater uptake of anti-VEGF-based treatments, an increasing imperative for early detection and intervention, more widespread application of combined drug and laser therapies, a heightened emphasis on managing diabetic eye complications, and the expansion of eye care services provided in outpatient and clinic settings.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
What Drivers Are Affecting Demand In The Macular Edema and Macular Degeneration Market?
The expanding diabetes population is projected to stimulate the growth of the macular edema and macular degeneration market in the future. Diabetes, a persistent medical condition, is characterized by elevated blood glucose (sugar) levels, which can damage the eye’s blood vessels, potentially resulting in macular edema and macular degeneration. For example, in June 2024, data from The National Health Service (NHS England), a publicly funded healthcare system in the UK, indicated that the count of individuals identified by the NHS in England with pre-diabetes reached 3,615,330 in 2023, marking an 18% increase from 3,065,825 in 2022. Moreover, cases among those under 40 escalated by nearly 25%, rising from 173,166 in 2022 to 216,440 in 2023. Thus, the increasing prevalence of diabetes is a significant driver for the growth of the macular edema and macular degeneration market.
Which Segments Are Gaining Traction In The Macular Edema and Macular Degeneration Market?
The macular edema and macular degeneration market covered in this report is segmented –
1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Subthreshold Laser Therapy, MicroPulse Laser Therapy
Which Competitive Trends Are Impacting The Structure Of The Macular Edema and Macular Degeneration Market?
Major companies active in the macular edema and macular degeneration market are concentrating on developing innovative solutions, such as continuous-delivery ocular implants, to lower the treatment burden, enhance patient adherence, and achieve more consistent long-term therapeutic outcomes. These continuous-delivery ocular implants are compact, refillable devices placed within the eye that gradually release medication over several months, thereby assisting patients by reducing the need for frequent injections and providing steady, prolonged treatment for retinal diseases. For instance, in February 2025, F. Hoffmann-La Roche Ltd, a biotechnology company based in Switzerland, obtained U.S. Food and Drug Administration (FDA) approval for Susvimo, a refillable ocular implant that delivers the anti-VEGF drug ranibizumab for treating diabetic macular edema (DME). Susvimo is engineered as a long-acting, surgically implanted reservoir that consistently releases a customised formulation of ranibizumab, maintaining therapeutic drug levels for extended periods. Unlike traditional anti-VEGF intravitreal injections, which typically demand monthly or bi-monthly dosing, Susvimo offers a refill-exchange interval of approximately six months, substantially decreasing the treatment burden for patients. Its sustained-delivery mechanism boosts adherence, streamlines clinical workflow, and offers lasting anatomical and visual benefits for individuals with chronic retinal disease.
Who Are The Top-Performing Companies In The Macular Edema and Macular Degeneration Market In Recent Years?
Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.
Access The Complete Report For Deeper Market Insights:
How Does The Macular Edema and Macular Degeneration Market Perform Across Major Global Regions?
North America was the largest region in the macular edema and macular degeneration market in 2025. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Macular Edema and Macular Degeneration Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp
Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2026, By The Business Research Company
Anemia And Other Blood Disorder Drugs Market Report 2026
Macular Degeneration Treatment Market Report 2026
Age Related Macular Degeneration Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
